The epidemiological landscape of candidiasis is undergoing a transformation, with a global shift observed from the historically predominant C. albicans to drug-resistant non-albicans Candida species (Quindós et al., 2018). The emergence of multidrug-resistant Candida species, notably C. auris, has been identified in over 40 countries worldwide and has diverged into four distinct genetic lineages (Rhodes and Fisher, 2019), revealing their global transmission patterns and diversity. Hospital environments are pivotal in the propagation of candidiasis, where Candida can survive and resist routine cleaning and disinfection measures (Erganis et al., 2024). Nevertheless, the prevalence of Candida in special environments or workplaces, such as farms, livestock, and slaughterhouses, requires further investigation.

Candida species primarily inhabit the human body (Fidel, 2011), with different species predominating in various infection sites. Oral and esophageal candidiasis are mainly caused by C. albicans, and vaginal candidiasis is also predominantly attributed to C. albicans, although it can also be linked to C. tropicalis and C. glabrata (Dabas, 2013). Skin and bloodstream candidiasis can be caused by multiple Candida species, including C. albicans, C. tropicalis, C. glabrata, and C. krusei (Williams et al., 2013; Fidel, 2011). Additionally, C. auris, an emerging pathogen, has been reported to cause infections in hospital settings and is capable of colonizing the skin of patients (Proctor et al., 2021).Candidiasis poses a significant challenge to public health, with clinical studies indicating that the mortality rate associated with Candida infections of the bloodstream, peritoneum, and other sites is alarmingly high (Figure 1), typically ranging from 25 to 60% within 30 days of diagnosis (Rajendran et al., 2016; Hirano et al., 2015; Bassetti et al., 2015). In the United States, the incidence of invasive candidiasis is as high as about 90 cases per 100,000 people, with a rising trend in non-bloodstream infections (Ricotta et al., 2021). This situation not only increases the hospitalization burden but also leads to a significant rise in the use of antifungal drugs, exacerbating the development of antifungal resistance (Parslow and Thornton, 2022; Oliva et al., 2023). From an economic perspective, the cost of hospitalization for candidiasis is high, accompanied by longer hospital stays and higher readmission rates, further straining the healthcare system (Ricotta et al., 2021).

In clinical practice, the diagnosis of candidiasis generally relies on clinical symptoms and laboratory examination results. Candidal vaginitis, the most common form of Candida infection, is mainly an inflammatory change in the vagina and vulva caused by Candida species, especially Candida albicans (Jeanmonod et al., 2025). For invasive candidiasis, the diagnosis is more challenging and requires a comprehensive assessment integrating clinical manifestations and laboratory tests such as Candida antigen detection (Barantsevich and Barantsevich, 2022). Currently, the diagnosis is typically carried out by first evaluating the patient’s symptoms related to the suspected candidiasis site. Then, relevant laboratory tests are conducted to confirm the presence and type of Candida. However, there are limitations in the existing diagnostic methods. Clinicians often rely on empirical treatment, such as the overuse of antibiotics like fluconazole, potentially overlooking critical diagnostic steps, including the detection of C. glabrata infections (C. glabrata has developed a resistance rate of up to 14.3% to fluconazole and is continuously rising) and conducting drug susceptibility testing (Poves-Alvarez et al., 2019; Zheng et al., 2024), which may in turn affect the overall treatment efficacy. This can lead to misdiagnosis and inappropriate treatment (Benedict et al., 2022; Huang et al., 2023). Additionally, detecting and identifying certain Candida species, like C. glabrata and C. parapsilosis, present difficulties (Sobel, 2022). These challenges in diagnosis can potentially affect the treatment outcome. In summary, current diagnostic methods for candidiasis have limitations, necessitating urgent exploration of new approaches. Genomics research may revolutionize diagnosis by enhancing accuracy and timeliness.

The genome of Candida is primarily composed of linear chromosomes, with the specific number and size varying among species. For instance, C. albicans possesses eight pairs of homologous chromosomes, whereas other species such as C. glabrata have 13 chromosomes (Selmecki et al., 2010; Helmstetter et al., 2022; Butler et al., 2009). Generally, the Candida genome contains numerous repetitive sequences and transposable elements, which may play crucial roles in gene regulation and evolution (Selmecki et al., 2010; Braun et al., 2005). The Candida genome also includes several gene families associated with pathogenicity, such as the ALS (adhesin) family and SAP (secreted aspartyl protease) family. These genes play a crucial role in the infection process of Candida (Ruiz-Herrera et al., 2006; Arnaud et al., 2009; Kabir et al., 2012). Moreover, the Candida genome exhibits a high degree of plasticity because of genomic instability, prone to chromosomal rearrangements, gene amplifications, and horizontal gene transfers, attributes closely associated with environmental adaptation and drug resistance (Butler et al., 2009; Selmecki et al., 2010; Helmstetter et al., 2022). Comparative genomics studies have unveiled the genomic instability among various Candida species, such as C. tropicalis and C. parapsilosis, which are associated with their pathogenic mechanisms and ecological adaptability (Butler et al., 2009; Desjardins et al., 2011). The genomic instability of Candida is primarily caused by multiple internal and external factors. Firstly, the genome is rich in repetitive sequences and active transposable elements that can easily trigger homologous recombination, leading to chromosomal rearrangements, deletions, or amplifications. Meanwhile, the dynamic changes in telomeres also increase the risk of chromosome fusion or breakage (Aguilera and García-Muse, 2013). Secondly, the alternation between sexual and asexual reproduction in Candida increases the possibility of genomic recombination, while the emergence of aneuploidy can rapidly alter gene dosage to adapt to environmental stress (Mba et al., 2022; Marton, 2020). Furthermore, environmental stresses such as temperature, pH, nutrient deficiency, and the use of antifungal drugs can also induce genomic instability (Aguilera and Gómez-González, 2008; Pais et al., 2019; Mba et al., 2022). Additionally, Candida can acquire exogenous genes from other microorganisms through horizontal gene transfer, further altering the genomic structure and acquiring new functions (Bezerra et al., 2013). Finally, defects in DNA repair mechanisms exacerbate genomic instability (Aguilera and Gómez-González, 2008). These factors collectively enable Candida to rapidly respond to environmental stress, enhance pathogenicity, and become a significant driving force for its environmental adaptation and evolution (Pais et al., 2019).Candidiasis poses a significant global health challenge, with the increasing prevalence of multidrug resistance and the emergence of novel pathogens complicating therapeutic interventions. Traditional research methods have limitations in accurately identifying Candida species, elucidating resistance mechanisms, and facilitating rapid diagnostics. In this context, genomic technologies have emerged as pivotal tools in the study of candidiasis, particularly through genome sequencing, comparative genomics, and functional genomics, which enable researchers to gain a deeper understanding of the pathogenic mechanisms and resistance characteristics of Candida (Figure 2). In recent years, significant progress has been made in the field of genomics in the study of candidiasis, allowing researchers to analyze the genetic features of Candida in detail and elucidate the complex relationships between its genetics, pathogenicity, and resistance. For example, Schikora-Tamarit and Gabaldón (2022) emphasized the central role of genomic sequencing studies in revealing the pathogenic mechanisms of Candida, providing important guidance for research in this field (Schikora-Tamarit and Gabaldón, 2022). Recently, Mathur et al. (2024) made new breakthroughs in this area. They utilized high-throughput genomic sequencing and bioinformatics analysis to successfully identify long non-coding RNAs (lncRNAs) in C. auris. These lncRNAs exhibit a distinct chromosomal distribution, with GC content concentrated between 40 and 45%, and most are predicted to be localized in the nucleus (Mathur et al., 2024). These findings suggest that lncRNAs may play important roles in regulating gene expression and maintaining genome stability. Furthermore, Mathur et al. (2024) observed differential expression patterns of lncRNAs at different infection stages, which could be intricately linked to the pathogenicity and drug resistance of C. auris, shedding new light on Candida’s pathogenic mechanisms. Additionally, through protein interaction network analysis, the researchers revealed potential interactions between lncRNAs and proteins, offering scientific evidence and potential targets for further exploring the development of drug resistance in Candida and the development of new therapies.

In terms of drug resistance, researchers have identified multiple gene mutations and mechanisms associated with resistance. Kannan et al. (2019) discovered 18 non-synonymous single nucleotide polymorphisms (SNPs) associated with multidrug resistance through comparative genomic analysis, with six SNPs being particularly implicated in resistance to various antifungal agents (Kannan et al., 2019). These findings indicate that genomic analysis not only provides clues to resistance mechanisms but also helps identify specific resistance genes. Czajka et al. (2023) summarized the antifungal drug resistance mechanisms of Candida species, pointing out that the development of resistance is primarily attributed to three factors: gene mutations, transcriptional regulation, and biofilm formation (Czajka et al., 2023). Moreover, Helmstetter et al. (2022) conducted an in-depth investigation into the microevolution of C. glabrata in clinical settings, revealing high levels of variation and recombination in mitochondrial genomes, pathogenic genes, and drug targets. This not only highlights the significant genetic diversity of C. glabrata but also demonstrates its capacity for rapid adaptability. It emphasizes that the inherent genetic diversity within C. glabrata populations may have a significant impact on its pathogenicity and drug resistance, with microevolution and genetic exchange/recombination being the two key primary drivers of this diversity (Helmstetter et al., 2022). Chow et al. (2020) traced the global spread history of the multidrug-resistant C. auris by comparing the genomes of 304 isolates, revealing its population structure and evolutionary relationships across different geographic regions (Chow et al., 2020). The results corroborate the hypothesis that C. auris may have spread to different countries through multiple independent introductions and provide insights into its global transmission patterns, which encompass multiple origins, geographic admixture, rapid evolutionary changes, and the maintenance of population structure. These findings are pivotal for public health surveillance, hospital infection control, and the development of personalized treatment strategies. However, the research did not extensively discuss the drug resistance characteristics of different lineages of C. auris and their relationship with genomic variations, thus necessitating the application of comparative genomics and further exploration.

Comparative genomics allows scientists to systematically compare the genomes of different Candida species, thereby identifying specific genes associated with pathogenicity and drug resistance. For example, Kannan et al. (2019) utilized comparative genomics to elucidate the genetic basis of multidrug resistance (MDR) mechanisms within the Candida genus, demonstrating that genomic analysis can identify important mutations (e.g., MRR1, FKS1, ERG3, and ERG4 gene) related to drug resistance (Kannan et al., 2019). Additionally, Maphanga et al. (2021) revealed the genetic basis of multidrug resistance in C. auris isolates from bloodstream infections through genomic analysis, identifying a suite of gene mutations associated with antifungal drug resistance, including ERG11, FKS1, UPC2, and FKS2 (Maphanga et al., 2021). These genes are also widely present in other Candida species (such as C. albicans, C. glabrata, and C. parapsilosis.), constituting a critical genetic basis for the multidrug resistance of Candida (Ibe et al., 2025; Boyce, 2023; Bédard et al., 2024; ElFeky et al., 2025). This provides new insights into the mechanisms of antifungal resistance in Candida and offers important reference data for clinical antifungal therapy.

In terms of virulence and resistance genes, significant differences and similarities exist among Candida species. For instance, in C. albicans, virulence is primarily regulated by adhesin genes (ALS family), hydrolase genes (SAP family), and morphogenesis-related genes such as EFG1 and CPH1 (Davari et al., 2019; Bras et al., 2024). In contrast, virulence of C. glabrata relies on the EPA family of adhesin genes and drug resistance-related genes such as CDR1 and PDH1 (Caudle et al., 2011). Notably, C. tropicalis and C. krusei exhibit unique virulence and resistance mechanisms, with C. tropicalis depending on the SAP family, which degrades host proteins to facilitate invasion and evasion of the host immune response, and also enables nutrient acquisition from the host, and BCR1 genes, which regulate cell wall remodeling, promote hyphal formation, assist Candida in adapting to different environments, resist host immune responses, and invade host tissues to initiate infection, while C. krusei demonstrates intrinsic resistance to fluconazole, potentially linked to mutations in the ERG11 gene (Pais et al., 2016; Modrzewska and Kurnatowski, 2015). Despite these differences, conserved mechanisms such as efflux pump genes and biofilm formation genes are shared across Candida species (Frías-De-León et al., 2021). However, variations in genome size and structure, gene family expansion, horizontal gene transfer, and specific virulence or resistance mechanisms highlight the diversity within the Candida genus (Zhou et al., 2021).

While the above studies have identified drug resistance-related gene mutations in pathogenic fungi at the genomic level, they lack further functional validation and mechanistic investigation, which limits a deeper understanding of resistance mechanisms. Consequently, there is an imperative for comprehensive research in functional genomics to elucidate the adaptive significance of these genes across different Candida species.

In the study of Candida functional genomics, to comprehensively explore the molecular basis of Candida drug resistance and pathogenic mechanisms, it is necessary to adopt various experimental methods for the validation of gene functions. Firstly, gene function validation experiments are one of the core methodologies. Through gene knockout or overexpression experiments, we can directly verify the roles that specific genes play in drug resistance and virulence of Candida species, such as C. glabrata and C. tropicalis (Gale et al., 2023; Paul et al., 2022). This method provides us with intuitive evidence demonstrating the impact of gene function on the biological characteristics of Candida. Secondly, expression analysis is also an indispensable part. Advanced technologies such as RNA sequencing can be utilized to deeply analyze the gene expression changes of Candida under different environmental conditions (e.g., antifungal drug treatment; Zuber et al., 2023; Helmstetter et al., 2022). By comparing the gene expression differences between resistant strains and sensitive strains, key genes related to drug resistance can be identified, providing important clues for subsequent research. Moreover, the application of genome sequencing technology has greatly advanced the development of Candida functional genomics. Through whole-genome sequencing, we are able to unveil the genetic variations between resistant and susceptible strains of Candida, which may involve critical aspects of the resistance mechanisms (Helmstetter et al., 2022; Burrack et al., 2022). Based on these findings, we can further explore the molecular mechanisms of drug resistance, providing a theoretical foundation for the development of novel antifungal agents. Finally, functional genomics analysis, as a systematic research approach, integrates data from multiple aspects including gene expression and genetic variation (Schikora-Tamarit and Gabaldón, 2022; Helmstetter et al., 2022; Burrack et al., 2022). Using this method, a more comprehensive understanding can be gained of how Candida regulates its genome to adapt to the host environment during the infection process. These comprehensive verifications and analyses not only contribute to unveiling the complex mechanisms of Candida resistance but also provide a scientific basis for formulating effective treatment regimens.

In functional genomics, researchers have explored how Candida species regulates its genome to adapt to the host environment during infection by analyzing gene expression and gene function. Schikora-Tamarit and Gabaldón (2022) highlighted that the study of genomic sequences is fundamental for identifying pathogenic and drug-resistant characteristics, emphasizing the importance of comparative genomics and population genomics in elucidating these traits (Schikora-Tamarit and Gabaldón, 2022). Building on the foundation of comparative genomics, studies using improved annotation tools, CRISPR-Cas9 technology, and long-read sequencing have shown that genomic alterations, such as gene expansion and horizontal gene transfer, are intimately linked to the emergence of fungal pathogenicity and drug resistance. Population genomics research has revealed the genetic structure of fungal pathogen populations, identifying genetic variants associated with these traits through genome-wide association studies. Moreover, directed evolution experiments have detected phenotypic mutations under controlled conditions, further simplifying the identification of mutations related to pathogenicity and drug resistance (Schikora-Tamarit and Gabaldón, 2022). Other studies, such as the Candida Comparative Genomics Project that sequenced and annotated multiple Candida species including C. albicans (WO-1), C. tropicalis, C. guilliermondii, and C. lusitaniae (Butler et al., 2009), population genomics research on C. albicans revealing evidence of gene flow and (para) sexuality in nature (Ropars et al., 2018), recent investigations on gene selection and drug resistance analyzing the genomes and phenotypes of 2,000 Candida strains (Schikora-Tamarit and Gabaldón, 2024), and studies utilizing direct RNA sequencing technology to examine the mitochondrial transcriptome of C. albicans (Piątkowski et al., 2024), have also made significant contributions to the understanding of this field.

In addition to direct whole genome sequencing for comparative genomics, transposon mutagenesis and transposon insertion site sequencing (Tn-seq) technologies play crucial roles in understanding Candida’s pathogenic mechanisms. Transposon mutagenesis technology is not only applicable for large-scale screening of genes affecting Candida virulence and identification of virulence factors but also for investigating the functions of genes that play a pivotal role during infection processes, thereby uncovering the functions of previously unknown genes and deepening our understanding of Candida biology (Kim et al., 2024; Zhou et al., 2024). Moreover, Tn-seq facilitates precise localization of transposon insertion sites, identifies affected genes, and promotes accurate studies of gene function, aiding functional genomics research to comprehensively elucidate the roles of genes in Candida virulence and adaptability (Nickels et al., 2024; Xiong et al., 2024). For instance, utilizing Tn-seq technology, researchers have identified multiple known virulence factors and novel genes critical for virulence and adaptability across the entire genome of C. glabrata, providing new insights into its pathogenic mechanisms (Nickels et al., 2024). Researchers have also employed functional genomics analysis using transposon mutant libraries to study the adaptability of C. albicans under various environmental conditions, discovering several important genes related to adaptability, including novel genes involved in cell wall synthesis, metabolism, and stress response (Xiong et al., 2024).

These above studies contribute significantly to understanding candidiasis by elucidating how genetic variations and mutations in Candida species affect their adaptability to host environments, virulence, and resistance to antifungal treatments, and by providing a solid foundation for the development of targeted therapeutic strategies and personalized treatment regimens (Jacobs et al., 2024; Schikora-Tamarit and Gabaldón, 2024).

In the study of candidiasis, to optimize treatment strategies and facilitate the creation of innovative antifungal drugs and diagnostic technologies, we should pay more attention to the following comparative genomics and functional genomics techniques. In the field of comparative genomics technology, noteworthy aspects include genome sequencing and alignment, evolutionary analysis, and genome collinearity analysis. These techniques can unveil the genomic diversity, evolutionary relationships, and structural similarities of Candida genomes, providing crucial information for understanding the adaptability and pathogenicity of Candida. Specifically, genome sequencing and alignment technologies can identify single nucleotide polymorphisms (SNPs), insertions/deletions (InDels), and structural variations (SVs) (Arafa et al., 2023). Evolutionary analysis aids in elucidating the evolutionary history of Candida and the mechanisms underlying the evolution of traits such as drug resistance (Morschhäuser, 2024). Meanwhile, genome collinearity analysis can detect events such as genome rearrangements and gene duplications (Arafa et al., 2023), which are closely related to the adaptability and pathogenicity of Candida. In the field of functional genomics technology, transcriptomics, gene knockout and knock-in technologies, as well as proteomics and metabolomics, all hold significant value. Transcriptomics can identify differentially expressed genes of Candida under various conditions (Xiong et al., 2024), providing clues for drug target prediction (Xiong et al., 2024). Gene knockout and knock-in technologies (e.g., CRISPR-Cas9) can directly elucidate the functions of specific genes in Candida growth, pathogenicity, and drug resistance, while also identifying potential drug targets (Wang et al., 2022). Proteomics and metabolomics further unveil the expression and regulatory mechanisms of functional genes in Candida (Xiong et al., 2024). In the study of candidiasis, these aforementioned techniques each have their own characteristics and complement each other. For instance, genome sequencing and alignment can pinpoint specific genetic variations that may confer drug resistance or enhance virulence (Gaston et al., 2025), while transcriptomics can reveal how these genetic changes impact gene expression patterns under different environmental conditions (Zhang et al., 2025). Gene knockout and knock-in technologies allow for the functional validation of these genes, confirming their roles in pathogenicity and drug resistance (Hou et al., 2025). Meanwhile, proteomics and metabolomics provide insights into the downstream effects of these genetic and transcriptional changes on cellular processes and metabolic pathways. Therefore, the research on candidiasis should comprehensively integrate these technologies to jointly promote the optimization of treatment strategies and the development of innovative antifungal drugs and diagnostic techniques.

In summary, the application of genomics technologies has markedly advanced in-depth research on candidiasis, providing a theoretical framework for clinical management and guiding the development of future antifungal drug development (Figure 2). However, considering the global challenge of candidiasis, it is still necessary to delve into the molecular mechanisms and evolutionary pathways of drug resistance. This exploration should be complemented by optimizing treatment strategies through comparative and functional genomics, as well as by fostering the creation of innovative antifungal drugs and diagnostic techniques. Through interdisciplinary collaboration and ongoing innovation, both greater breakthroughs in the research and treatment of candidiasis are anticipated.

Candida, a significant human pathogenic fungus, its pathogenic characteristics are primarily manifested in biofilm formation and the action of virulence factors (Figure 3). Biofilm formation is a key feature of Candida infections, significantly enhancing its tolerance to antifungal drugs. These biofilms are typically complex structures composed of fungal cells, extracellular matrix, and other microbial symbionts, forming a protective barrier that shields Candida from both the host’s immune response and antifungal treatment attacks (Gómez-Gaviria and Mora-Montes, 2020). Further research, such as that revealed by Kumar and Kumar (2024), indicates that the biofilm formation mechanism in C. albicans involves multiple molecular determinants, including the precise regulation by transcription factors (e.g., CaNdt80p, Bcr1, and Efg1) and regulatory factors (e.g., Ras1-Cdc35, Cyr1, and Stt4-Mss4-Sfk1). These factors work in concert to control the expression of genes related to adhesion, hyphal/pseudohyphal growth, persister cell transformation, and overall biofilm formation. Notably, Cyr1, as an adenylate cyclase, plays a central role in the Ras/cAMP signaling pathway, catalyzing the production of cAMP, which serves as a crucial second messenger in regulating hyphal growth and various other cellular responses. Additionally, the Ras1 protein, a key component of the Ras/cAMP signaling pathway, not only participates in the regulation of cell shape but also exerts precise control over various stress responses, which is essential for nutrient sensing and uptake in C. albicans. Moreover, Cdc35, another adenylate cyclase, plays a significant role in the regulation of hyphal growth in C. albicans. The complex gene expression differences and regulation within the biofilm not only lead to adaptive changes in the morphology and metabolism of Candida but also enable it to form a robust protective barrier composed of fungal cells, an extracellular matrix, and other microbial symbionts. This barrier effectively resists attacks from the host immune system and exhibits significant resistance to antifungal treatments (Kumar and Kumar, 2024). Furthermore, previous studies have indicated that Candida promotes its colonization and infection capabilities by forming biofilms on host tissues and medical implants (Villard et al., 2015; Shinde et al., 2012; Gao et al., 2013), corroborating the latest findings on C. albicans biofilm formation mechanisms by Kumar and Kumar (2024). This highlights the critical role and complexity of Candida biofilms in their pathogenic processes. According to a recent study by Zeng et al. (2023), Rubiginosin C can effectively inhibit the biofilm formation and morphological transitions of C. auris and C. albicans, thereby exerting an inhibitory effect without causing lethal effects on host cells (Zeng et al., 2023). This finding underscores the importance of biofilms in the challenges of antifungal therapy and provides strong support for the development of novel antifungal drugs.

The pathogenicity of Candida is closely related to its multiple virulence factors. On one hand, Candida can produce various enzymes, such as proteases and lipases, which are instrumental in the invasion and damage of host tissues. For example, Lin et al. (2024) demonstrated that C. albicans can secrete candidalysin, a protease or cytolytic peptide toxin, which targets the sulfated glycosaminoglycans of host epithelial cells (Lin et al., 2024). This indicates that Candida can degrade host cell structures by releasing enzymes to obtain nutrients and enhance its survival capabilities (Bhattacharya et al., 2020). On the other hand, the adhesins on the surface of Candida also significantly influence its pathogenicity. These adhesins, such as Als3, are multifunctional, not only promoting cell adhesion but also participating in cell invasion, thereby helping Candida effectively attach to host cells (Baillie and Douglas, 1999). Additionally, these adhesins can mediate the translocation of Candida across the intestinal barrier, leading to systemic infections (Chong et al., 2018; Mochon et al., 2010).

Collectively, the pathogenic characteristics of Candida are primarily achieved through the formation of biofilms and the action of multiple virulence factors (Table 1), which enable it to successfully survive and cause infections in various host environments.

In the pathogenic mechanisms of Candida, core virulence factors (Table 1) play a vital role. Key virulence factors encompass a spectrum of enzymes and adhesion proteins that synergistically target the host to facilitate infection onset and progression.

With the widespread use of antifungal agents, antifungal resistance in Candida species has become an increasingly severe issue. This resistance issue is mediated by a variety of mechanisms that are species-specific and can be categorized as follows (Figure 4):

Currently, the treatment strategies for candidiasis predominantly focus on the use of antifungal drugs, but the issue of drug resistance is becoming increasingly severe, which imposes a significant medical and economic burden. Therefore, it is crucial to explore new treatment methods and preventive measures. Genomics has shown broad application prospects in candidiasis research and offers new avenues and methods for its research and treatment (Lass-Flörl et al., 2024; Rhodes and Fisher, 2019). By conducting in-depth analysis of the Candida genome, researchers can uncover resistance mechanisms, achieve a better understanding of their virulence factors and regulatory mechanisms, providing a theoretical foundation for the development of new diagnostic and therapeutic strategies (Rhodes and Fisher, 2019; Fidel, 2011; Rybak et al., 2022; Chen et al., 2024). These research findings not only enhance the overall understanding of candidiasis but also promote the development of precision medicine, which could help alleviate and address the pressures and challenges of related public health issues. These research advances provide theoretical support for developing new therapeutic strategies, while specific treatment methods are continually being explored.

Based on the achievements of genomic research, investigators are exploring a multitude of novel therapeutic strategies. Alternative therapies for Candida infections and biofilm disruption strategies offer new perspectives for clinical treatment. Research has found that natural plants such as sesame, sesame leaves, and honeysuckle contain antifungal components that can be used to treat oral candidiasis. They are being explored as alternative options for antifungal drugs, capable of inhibiting the growth of oral Candida (Contaldo et al., 2023). Meanwhile, probiotic therapy, particularly strains such as Lactobacillus sp. and Bifidobacterium sp., effectively prevents the recurrence of Candida infections on oral mucosa and skin surfaces by restoring microbial balance at the infection sites. With low toxicity, it offers a safer treatment option in clinical settings (Contaldo, 2023; Fusco et al., 2023; Ricci et al., 2022). Moreover, photodynamic therapy utilizes photosensitizers and specific wavelengths of light to selectively destroy Candida cells. This method offers advantages such as non-induction of drug resistance, high selectivity, and low toxicity, introducing a novel physical approach for the treatment of Candida infections (Contaldo et al., 2023). Additionally, biofilm degradation strategies employ methods such as enzymes (like DNase) and metal chelators to break down fungal biofilms associated with Candida infections. This indirectly inhibits fungal growth and is particularly suitable for cases of recurrent or refractory Candida infections, providing a new approach to enhance the efficacy of antifungal drugs and reduce infection recurrence rates (Contaldo et al., 2023; Contaldo, 2023; Fusco et al., 2023; Chanda et al., 2017). These strategies and research prospects have opened new avenues for the clinical treatment of candidiasis infections, warranting further in-depth investigation and exploration.

Despite considerable research on antifungal resistance, further exploration is needed to understand how different Candida species develop resistance in various environments. Particularly, the complexity and severity of resistance in emerging species or strains, such as C. auris, have garnered significant attention (Rybak et al., 2022). C. auris exhibits multidrug resistance, showing resistance to commonly used antifungal agents like polyenes, echinocandins, and 5-FC (Bhattacharya et al., 2020; Rybak et al., 2022). Therefore, in-depth investigation into the specific changes in resistant genes during the mutation process and the transmission of these mutant genes within Candida populations has become a current research focus. However, existing research still faces some challenges and limitations. For example, in-depth studies on the Candida resistance mechanisms require high-precision experimental techniques and complex data analysis methods (Branco et al., 2023), demanding high levels of expertise and experimental conditions. Additionally, Candida resistance mechanisms may be influenced by multiple factors, including environmental factors and host immune status (Costa-de-Oliveira and Rodrigues, 2020; Czajka et al., 2023), and the interactions between these factors make the research even more complicated. To address these challenges, future research could explore the following aspects: First, continue to deepen the fundamental research on the mechanisms of Candida drug resistance mechanisms to uncover additional unknown resistance mechanisms; Second, strengthen interdisciplinary collaboration and utilize advanced technologies, such as bioinformatics and genomics, to conduct more comprehensive analysis and prediction of Candida drug resistance; Finally, foster the innovative development of antifungal drugs and therapeutic strategies to provide more effective solutions for combating the threat of emerging drug-resistant Candida. In particular, systematic research on the variation and transmission mechanisms of resistance genes in emerging drug-resistant species or strains, such as C. auris, and the formulation of targeted treatment strategies will be the top priority for future research (Jangir et al., 2023). Only through in-depth research and continuous exploration can we better understand and address the challenges of Candida drug resistance, ensuring the safeguarding of human health.

With the rapid advancement of genomics technology, we are entering a new era where personalized treatment of Candida infections based on individual genomic characteristics is becoming feasible. Currently, in-depth analysis of the genomic data of approximately 2,000 primary Candida species (Schikora-Tamarit and Gabaldón, 2024), alongside genomic studies of emerging pathogens such as C. albicans (Bruno et al., 2021), has shed light on the genetic diversity and resistance mechanisms of Candida. Additionally, the integration of transcriptomic analysis and functional genomics approaches has provided new insights into the interactions between Candida and host defense mechanisms, offering new perspectives for personalized therapy. In the future, further exploration of the relationship between Candida resistance genomics and clinical treatment responses is expected to provide a scientific basis for personalized medicine (Stalder et al., 2023). However, achieving personalized treatment for Candida infections necessitates a holistic examination of pharmacokinetics and pharmacogenomics, and other pertinent factors (Daneshnia et al., 2023). Interdisciplinary collaboration and resource integration will be key to advancing this field.

Attention should be focused on the development of new antifungal drugs, particularly those targeting multidrug-resistant Candida strains, which is essential for improving treatment outcomes. With the continuous advancement of genomics technology, personalized treatment based on the individual genomic characteristics of Candida may become a reality, laying the foundation for personalized medicine. To effectively address the challenge of multidrug-resistant Candida, researchers are actively employing strategies such as drug repositioning, identification of novel targets, and the discovery or synthesis of novel compounds to explore novel antifungal drugs that can effectively inhibit these resistant strains. Meanwhile, by integrating multi-omics research methods, including transcriptomics and metabolomics, new drug targets and combination therapy strategies are being further explored to enhance treatment efficacy (Brackin et al., 2021). For example, Candida biofilms have been identified as a promising target (Kovács et al., 2021; Jamiu et al., 2021), and combination therapies may potentially overcome their resistance in the future. Collectively, the development of new antifungal drugs in combination with multi-omics research methods will be an important and effective strategy for improving the treatment outcomes of multidrug-resistant Candida.

Considering the transmission characteristics of Candida, comprehensive and in-depth measures are imperative to address the public health challenges posed by Candida infections. Strengthening public health surveillance, particularly infection control in hospital environments, should be a priority. This includes implementing strict contact isolation policies, ensuring thorough environmental cleaning and disinfection to curb the spread of Candida within hospitals. Additionally, promoting international cooperation to facilitate information sharing and coordinated responses on a global scale is crucial for this cross-border challenge (Rhodes and Fisher, 2019). Close collaboration between public health departments and healthcare institutions is also indispensable, as each brings its own expertise in areas such as surveillance and early warning, the development of prevention and control strategies, and patient diagnosis and treatment. Such collaborative efforts can markedly enhance the effectiveness of control measures (Borman and Johnson, 2020). The development of new drugs targeting drug-resistant Candida is urgent, utilizing multi-omics research methods to explore new drug targets and combination therapy strategies will open new avenues for treating drug-resistant Candida infections (Janniger and Kapila, 2021).

In summary, comprehensive strengthening of surveillance, international cooperation, hospital infection control, inter-departmental collaboration, and new drug development are key strategies for addressing the public health issue of Candida infections. Through in-depth exploration of these research directions, a better understanding of the pathogenic mechanisms and drug resistance of Candida infections can be achieved, ultimately facilitating the development of more effective prevention and treatment strategies.